ȯÀÚÀÇ Àå±â »ýÁ¸À» À§ÇØ ÃÖ¼±À» ´ÙÇÏ´Â °£¾Ï ¹× °£Áúȯ Àü¹®°¡
ÇöÀç ¼¿ï¼º¸ðº´¿ø ¼Òȱ⳻°ú ±³¼ö·Î ÀçÁ÷ ÁßÀ̸ç, °¡Å縯ÀÇ´ë ÀǰúÇаú¿Í µðÁöÅÐÇコÇаú¿¡¼µµ ±³¼ö·Î Ȱµ¿Çϰí ÀÖ´Ù. ´ëÇѼÒȱâÇÐȸ, ´ëÇѰ£ÇÐȸ, ´ëÇѰ£¾ÏÇÐȸ µî¿¡¼ À§¿øÀ¸·Î Ȱµ¿ÇØ ¿ÔÀ¸¸ç, ÁÖ¿ä ¿¬±¸ ºÐ¾ß´Â ¡ã°£¾ÏÀÇ ¸é¿ª¡¤¼¼Æ÷ Ä¡·á ¡ã°£¿°¡¤°£°æº¯ÀÇ ¿øÀÎ ±Ô¸í°ú Ä¡·á´Ù. ±âÃÊ ¿¬±¸¿¡¼ ÀÓ»ó Àû¿ë±îÁö Æø³ÐÀº °æÇèÀ» ¹ÙÅÁÀ¸·Î, °£ ÁúȯÀÇ Á¶±â Áø´Ü°ú ¸ÂÃãÇü Ä¡·á Àü·« °³¹ß¿¡ Èû¾²°í ÀÖ´Ù.
| Á¦ ¸ñ | Immune responses and immunopathology in acute and chronic viral hepatitis | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2016 | ¹ßÇ¥Áö | Nature Reviews Immunology. |
| Á¦ ¸ñ | Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Hepatology |
| Á¦ ¸ñ | Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | Clinical and molecular hepatology |
| Á¦ ¸ñ | Intrahepatic inflammatory IgA + PD-L1 high monocytes in hepatocellular carcinoma development and immunotherapy | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | Journal for Immunotherapy of cancer |
| Á¦ ¸ñ | Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2025 | ¹ßÇ¥Áö | Liver cancer |
| Á¦ ¸ñ | EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1 | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2020 | ¹ßÇ¥Áö | Journal for Immunotherapy of cancer |
| Á¦ ¸ñ | Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | Biomedicine and pharmacotherapy |
°£¾ÏÀÇ ´ÙÇÐÁ¦Àû Ä¡·á ¹× ¸é¿ªÇ×¾ÏÄ¡·á¿Í °£Áúȯ ¸é¿ªÇÐ ºÐ¾ß¿¡ °¡Àå ±íÀº °ü½É°ú Àü¹®¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÓ»ó ¿¬±¸ »Ó ¾Æ´Ï¶ó ±âÃÊ ¿¬±¸¿¡¼µµ µÎ°¢À» ³ªÅ¸³»°í Àִµ¥, ÃÖ±Ù ¿¬±¸´Â °£¾ÏÀÇ ¸é¿ª Á¶Àý ±âÀü°ú ¸é¿ª ȸº¹À» ÅëÇÑ Ä¡·á Àü·« °³¹ß¿¡ ÃÊÁ¡ÀÌ ¸ÂÃß¾îÁ® ÀÖ½À´Ï´Ù.
ȯÀÚ Áø·á¿¡¼ Áúº´ÀÇ Ä¡·á»Ó ¾Æ´Ï¶ó ±âÀú ÁúȯÀÇ °ü¸®¿Í »îÀÇ Áú Çâ»óÀ» µ¿½Ã¿¡ ´Þ¼ºÇÒ ¼ö ÀÖ´Â Àü·«À» µµÃâÇÏ´Â °ÍÀ» °¡Àå Áß¿äÇÏ°Ô ¿©±ä´Ù. ´Ü¼øÈ÷ °Ë»ç °á°ú³ª ¿µ»ó ¼Ò°ß¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ȯÀÚÀÇ º´·Â¡¤»ýȰ½À°ü¡¤½É¸®Àû ¹è°æ±îÁö Á¾ÇÕÀûÀ¸·Î °í·ÁÇÏ¿© ¸ÂÃãÇü Áø´Ü°ú Ä¡·á¸¦ Ãß±¸ÇÑ´Ù. ¶ÇÇÑ ±Ù°Å Á᫐ ÀÇÇÐ(Evidence-based medicine) ¿¡ ±â¹ÝÇϵÇ, ÀÓ»óÀÇÀÇ °æÇè°ú Á÷°üÀ» Á¶È½ÃŰ´Â °ÍÀ» ÇÙ½É °¡Ä¡·Î »ï°í ÀÖ´Ù.
¹«¾ùº¸´Ù Àú´Â ¾î¶² »óȲ¿¡¼µµ ȯÀÚ¸¦ ³¡±îÁö, Àý´ë·Î Æ÷±âÇÏÁö ¾Ê°Ú½À´Ï´Ù. ¶ÇÇÑ Àú´Â ȯÀÚÀÇ º´¸¸ÀÌ ¾Æ´Ï¶ó »î Àüü¸¦ ÇÔ²² µ¹º¸´Â Àǻ簡 µÇ°íÀÚ ÇÕ´Ï´Ù. º´ÀÇ ¿øÀΰú Ä¡·á, ±×¸®°í ±× µÚ¿¡ Àִ ȯÀÚÀÇ »ýȰ°ú ¸¶À½±îÁö »ìÇÇ¸ç ´õ ³ªÀº »îÀÇ ÁúÀ» ¸¸µé¾î °¡°Ú½À´Ï´Ù. °úÇÐÀû ±Ù°Å¿Í ÀÓ»ó °æÇèÀ» ¹ÙÅÁÀ¸·Î, ȯÀÚ ÇÑ ºÐ ÇÑ ºÐ¿¡°Ô °¡Àå ÀûÇÕÇÑ ±æÀ» ÇÔ²² ã¾Æ°¡°Ú½À´Ï´Ù.

°¡Å縯´ë¼¿ï¼º¸ðº´¿øÀº 1980³â °³² Áö¿ª ÃÖÃÊÀÇ Á¾ÇÕº´¿øÀ¸·Î ¼¼¿öÁ³´Ù. ÇöÀç Áö»ó 22Ãþ, ÁöÇÏ 6ÃþÀÇ 1355º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖÀ¸¸ç ´ÜÀÏ °Ç¹° º´¿øÀ¸·Î´Â ±¹³» ÃÖ´ë ±Ô¸ðÀÌ´Ù. °¡Å縯´ë¼¿ï¼º¸ðº´¿øÀº °¡Å縯±³È¸ÀÇ ´ëÇ¥ º´¿øÀ¸·Î °¡Å縯Áß¾ÓÀÇ·á¿øÀÇ ÀÌ³ä ½Çõ¿¡ Àû±Ø ¾ÕÀå¼°í ÀÖÀ¸¸ç, ȯÀÚ¸¦ ¸ÕÀú »ý°¢ÇÏ´Â Àü¹®¼¾ÅÍ Áß½ÉÀÇ º´¿ø, 21¼¼±â ÃÖ÷´Ü ÀÇ·á ½Ã½ºÅÛ º´¿øÀ¸·Î °Åµì³ª°í ÀÖ´Ù.
¼¿ïƯº°½Ã ¼Ãʱ¸ ¹ÝÆ÷´ë·Î 222